FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($1.88), $1.79 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.35 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.